- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Interferon regulatory factors.
Displaying page 1 of 1.
EudraCT Number: 2021-001270-34 | Sponsor Protocol Number: RIMAL1 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:Radboud University Medical Centre | |||||||||||||
Full Title: Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system). | |||||||||||||
Medical condition: patients with recurrent / refractory 9p24.1 amplified malignant lymphomas patients with recurrent / refractory malignant lymphoma without 9p24.1 amplification | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000994-30 | Sponsor Protocol Number: VD1.3 | Start Date*: 2013-02-19 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: A randomized, double‐blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on metabolic and fertility parameters in PCOS women | ||
Medical condition: Polycystic Ovary Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006644-19 | Sponsor Protocol Number: CRISTAL | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003575-11 | Sponsor Protocol Number: VitaminD&TT | Start Date*: 2013-03-05 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Innere Medizin | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men | |||||||||||||
Medical condition: Male hypogonadism (total testosterone <3ng/ml) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005989-38 | Sponsor Protocol Number: | Start Date*: 2012-11-01 |
Sponsor Name:Norwegian University of Science and Technology | ||
Full Title: A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA | ||
Medical condition: Chronic myeloid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) FI (Completed) SE (Ongoing) DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002178-22 | Sponsor Protocol Number: 11-AVR-130 | Start Date*: 2011-12-26 | |||||||||||
Sponsor Name:Avanir Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ... | |||||||||||||
Medical condition: Central Neuropathic Pain in Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010273-20 | Sponsor Protocol Number: 18081 | Start Date*: 2012-11-28 | |||||||||||
Sponsor Name:European organisation for research and treatment of Cancer | |||||||||||||
Full Title: Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. | |||||||||||||
Medical condition: Ulcerated primary cutaneous melanoma >1mm (T2b-4bN0M0) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed) DK (Completed) ES (Completed) NL (Completed) PT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
